Provexis appoints Dr Niamh O’Kennedy to its Board as CSO alongside Dawson Buck stepping to Non-Executive Chairman

– UK, Reading –  Provexis (LON:PXS), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow heart-health functional food ingredient, today announced the appointment of Dr Niamh O’Kennedy as an Executive Director of the Company, and as Chief Scientific Officer, with immediate effect.

Niamh is a research chemist, specialising in the field of natural products chemistry, who has been working with Provexis since 2000. Niamh’s experience in isolating and characterising plant-derived compounds and understanding the roles these play in complex biological systems has been pivotal in the development of Provexis’ lead product, Fruitflow, and the health claim for Fruitflow which was adopted by the European Food Safety Authority.

In conjunction with Niamh’s appointment, Ian Ford’s role has been expanded to Chief Financial Officer and Chief Operating Officer and Dawson Buck’s role has changed from Executive Chairman to Non-executive Chairman. These changes, which are effective immediately, have taken place to reflect the revised board composition and roles of the directors, and they will result in a net reduction to the total cash remuneration payable to these three individuals.

The Company’s financial year ended on 31 March 2019 and the board expects to provide an update on trading before the end of the current quarter to 30 June 2019.

Dawson Buck, Non-executive Chairman of Provexis, commented: ‘I am delighted that Niamh is joining the board as an executive director.

The Company remains well placed to maximise the numerous commercial opportunities which the Company and DSM have been pursuing for Fruitflow, to include the Company’s planned collaboration with By-health in the vast Chinese market, and Niamh is expected to play an important role for the business as these opportunities are progressed.’

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow heart-health functional food ingredient.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For more information : http://www.provexis.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.